Chronic actinic dermatitis responding to danazol

P Humbert; C Drobacheff; M. Vigan; K. QUENCEZ; E Quencez; R. Laurent; P Agache

doi:10.1111/j.1365-2133.1991.tb00433.x

Chronic actinic dermatitis responding to danazol

P Humbert, C Drobacheff, M. Vigan, K. QUENCEZ, E Quencez, R. Laurent, P Agache

The British journal of dermatology · 1991 · vol. 124(2) , pp. 195–197 · doi:10.1111/j.1365-2133.1991.tb00433.x · PMID:2004006 · W1984163982

Case report OA: closed CC0

View on OpenAlex View on PubMed View at publisher

⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-12 ⓘ

A patient with chronic actinic dermatitis and alpha-1-antitrypsin deficiency experienced a positive response to danazol treatment.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

We report an unusual case of chronic actinic dermatitis associated with α1‐antitrypsin deficiency and who responded well to treatment with danazol.

My notes (saved in your browser only)

MeSH descriptors

Danazol Photosensitivity Disorders Aged alpha 1-Antitrypsin Deficiency Chronic Disease Danazol Face Face Humans Male Photosensitivity Disorders Photosensitivity Disorders Photosensitivity Disorders

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (4)

References (24)

Beneficial effects of danazol on symptoms and laboratory changes in cholinergic urticaria via openalex
Danazol for the treatment of refractory autoimmune thrombocytopenia in systemic lupus erythematosus via openalex
Danazol therapy for autoimmune hemolytic anemia via openalex
The treatment of glucocorticosteroid-dependent chronic urticaria with stanozolol via openalex
W2409794994 via openalex
doi:10.1001/archderm.114.6.921 via openalex
doi:10.1172/jci109838 via openalex
doi:10.1016/0090-1229(85)90097-2 via openalex
doi:10.1016/s0190-9622(89)70328-5 via openalex
doi:10.1111/j.1365-2133.1985.tb00076.x via openalex
doi:10.1111/j.1365-2230.1981.tb02375.x via openalex
doi:10.1111/j.1365-2133.1989.tb08197.x via openalex
doi:10.1001/archderm.118.5.339 via openalex
doi:10.1111/j.1365-2133.1985.tb02309.x via openalex
doi:10.1016/0002-9343(88)90154-4 via openalex
doi:10.1038/298329a0 via openalex
doi:10.1111/j.1365-2133.1989.tb01804.x via openalex
doi:10.1001/archderm.1978.01640180055013 via openalex
doi:10.1001/archderm.111.8.979 via openalex
doi:10.1111/j.1365-2133.1980.tb15835.x via openalex
doi:10.1136/bmj.2.1125.130 via openalex
W2034848328 via openalex
doi:10.1001/archderm.1982.01650170053024 via openalex
doi:10.4049/jimmunol.130.2.681 via openalex

Source provenance

openalex: last seen: 2026-05-11T06:10:27.824888+00:00
pubmed: last seen: 2026-10-08T21:07:11.085580+00:00

License: CC0 · commercial use OK

[1] Danazol therapy for autoimmune hemolytic anemia 1985

[2] Danazol for the treatment of refractory autoimmune thrombocytopenia in systemic lupus erythematosus 1988

[3] The treatment of glucocorticosteroid-dependent chronic urticaria with stanozolol 1988

[4] Beneficial effects of danazol on symptoms and laboratory changes in cholinergic urticaria 1987